secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADAPTIN BIO, INC. (APTN)
CIK:        0001938571
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001213900-25-014630
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.02, 1.01, 3.03, 4.01, 5.01, 5.02, 5.03, 5.05, 5.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptin Bio completes reverse merger with private biotech, raises ~$4.76M in private placement
--------------------------------------------------------------------------------

- Merger between Unite Acquisition (shell) and Private Adaptin closed Feb 11, 2025; Private Adaptin becomes wholly owned subsidiary.
- Issued ~3.25M shares to Private Adaptin stockholders; former shell stockholder Lucius Partners retains 3.25M shares.
- Concurrent private placement of 1,080,814 Units at $4.40/Unit raised $4,755,581; each Unit: one share, one A warrant, one-half B warrant.
- $1.5M bridge notes plus accrued interest converted into 501,140 shares and pre-merger warrants issued.
- Company to file resale registration statement within 60 days after offering termination; OTC Markets QB listing planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/ea0230169-8k_adaptin.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-014630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer